Concomitant chemoradiation for head and neck cancer: Saving lives or grays?

Clinical Oncology

Volumn 13, Issue 5, 2001, Pages 333-335

  Henk, J M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DNA; FLUOROURACIL; METHOTREXATE; MITOMYCIN; NIMORAZOLE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEAD AND NECK CANCER; HOSPITALIZATION; HUMAN; METASTASIS; MORBIDITY; MUCOSA INFLAMMATION; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 0034759051     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9284     Document Type: Editorial

References (14)

1. Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial
2. Synchronous chemoradiation of squamous carcinoma: This has become the gold standard - Whatever the primary site
3. Some observations on the combined effects of X-rays and methotrexate on human tumour cells in vitro with possible relevance to their most useful combination in radiotherapy
4. Chemotherapy added to loco-regional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
5. Hyperfractionation compared with conventional radiotherapy in oropharyngeal carcinoma: An EORTC randomized trial
6. Radiation Therapy Oncology Group Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell RTOG 9003
7. The DAHANCA 6&7 trial of 5 vs 6 fractions per week of conventional radiotherapy of squamous-cell carcinoma of the head and neck: A randomised study with 1485 patients
8. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: Overview of radiation morbidity
9. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer
10. UKHAN 1: A prospective multi-centre randomised trial investigating chemotherapy as part of initial management in advanced head and neck cancer
11. Radiotherapy combined with mitomycin C in the treatment of locally advanced head and neck cancer. First report from the IAEA-CRP E3.30.13 randomised multicentre study
12. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
13. Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: Clinical and pharmacological data of a French multi-centre study
14. A randomized double-blind Phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85